subscribeSubscribe
Ardelyx Presents IBSRELA IBS-C Data At DDW 2024

Ardelyx Presents IBSRELA IBS-C Data At DDW 2024
GLOBENEWSWIRE
21 May 2024
Share Share
Ardelyx Presents Additional XPHOZAH Data At NKF 2024

Ardelyx Presents Additional XPHOZAH Data At NKF 2024
GLOBENEWSWIRE
16 May 2024
Share Share
Ardelyx To Present IBSRELA Data At Digestive Disease Week 2024

Ardelyx To Present IBSRELA Data At Digestive Disease Week 2024
GLOBENEWSWIRE
07 May 2024
Share Share
Ardelyx Q1 2024 Results, Business Update

Ardelyx Q1 2024 Results, Business Update
GLOBENEWSWIRE
02 May 2024
Share Share
Ardelyx: XPHOZAH Data In Kidney Disease At NKF 2024 Meeting

Ardelyx: XPHOZAH Data In Kidney Disease At NKF 2024 Meeting
GLOBENEWSWIRE
01 May 2024
Share Share
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA

XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA
GLOBENEWSWIRE
15 Nov 2023
Share Share
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA

Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA
GLOBENEWSWIRE
23 Oct 2023
Share Share
US FDA approves Ardelyx`s kidney disease-related drug

US FDA approves Ardelyx`s kidney disease-related drug
REUTERS
18 Oct 2023
Share Share
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia

Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia
GLOBENEWSWIRE
13 Oct 2023
Share Share
Ardelyx Shares Preliminary Data on Use of IBSRELA in Pediatric IBS-C Patients

Ardelyx Shares Preliminary Data on Use of IBSRELA in Pediatric IBS-C Patients
GLOBENEWSWIRE
04 Oct 2023
Share Share